glp-1 agonists and sglt2 inhibitors Receptor in Diabetic Kidney Disease: Evolving Evidence and Clinical Application View of Diabetes medications with

Together, these two incretins contribute to metabolic homeostasis, preventing both hyperglycemia and hypoglycemia, mitigating dyslipidemia, and reducing the risk of cardiovascular diseases in individuals with type 2 diabetes and obesity

Concerns about whether GLP-1 receptor agonists cause pancreatic cancer emerged from early animal studies and post-marketing reports, prompting regulatory investigations

Effects of ondansetron on symptoms during a gastric emptying study and enteral lipid challenge and on daily symptoms in diabetic gastroenteropathy

Small peptides like GLP-1 and GLP-2 are rapidly cleared in vivo , leading to low circulating levels

[DOI] [PMC free article] [PubMed] [Google Scholar] 92.Chen D, Li Q, Liang H, Huang L, Zhou H, Zheng X, et al

2015, pp